List of Excipients in Branded Drug DYE-FREE IBUPROFEN 200

Generic Drugs Containing DYE-FREE IBUPROFEN 200

Company	Ingredient	NDC	Excipient
WALGREEN COMPANY	ibuprofen	0363-0103	GELATIN
WALGREEN COMPANY	ibuprofen	0363-0103	POLYETHYLENE GLYCOL
WALGREEN COMPANY	ibuprofen	0363-0103	POTASSIUM HYDROXIDE
WALGREEN COMPANY	ibuprofen	0363-0103	SORBITAN
WALGREEN COMPANY	ibuprofen	0363-0103	SORBITOL
WALGREEN COMPANY	ibuprofen	0363-0103	WATER

What are the Most Frequently-Used Excipients in DYE-FREE IBUPROFEN 200?

# Of NDCs	Excipient
2	GELATIN
2	POLYETHYLENE GLYCOL
2	POTASSIUM HYDROXIDE
2	SORBITAN
2	SORBITOL
2	WATER

Dye-Free Ibuprofen 200 mg: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 27, 2026

Dye-free ibuprofen 200 mg is a low-barrier OTC analgesic opportunity centered on formulation execution, manufacturing cost, retailer access, and consumer positioning rather than molecule-level exclusivity. Ibuprofen is a mature active ingredient with broad generic availability. The principal commercial levers are tablet performance, excipient transparency, allergen control, packaging, private-label distribution, and differentiated dosage forms.

What is dye-free ibuprofen 200 mg?

Dye-free ibuprofen 200 mg is an immediate-release oral analgesic containing 200 mg of ibuprofen as the active ingredient. In the U.S., the product is generally marketed under the FDA OTC monograph framework for internal analgesic, antipyretic, and antirheumatic products, subject to applicable conditions of use, labeling, dosage, and manufacturing requirements.[1]

A standard adult and pediatric dose for consumers age 12 and older is 200 mg to 400 mg every four to six hours, with a labeled maximum of 1,200 mg in 24 hours unless directed by a physician.[2]

"Dye-free" normally means that the formulation does not contain synthetic or declared color additives used to color the tablet, coating, capsule shell, or liquid. It does not necessarily mean that the product is free of:

• Titanium dioxide or other opacifying agents
• Artificial flavors
• Gelatin
• Lactose or other allergens
• Polyethylene glycol
• Sodium-containing excipients
• Corn-, potato-, or wheat-derived materials

The commercial value of the claim depends on the full inactive-ingredient list and the strength of the product's labeling substantiation.

What excipients are used in dye-free ibuprofen 200 mg tablets?

Common excipient categories include fillers, binders, disintegrants, lubricants, glidants, and film-coating materials. The exact composition varies by manufacturer and dosage form.

Excipient function	Common options	Commercial relevance
Diluent or filler	Microcrystalline cellulose, starch, lactose, dibasic calcium phosphate	Controls tablet size, compression, and cost
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves tablet strength
Disintegrant	Croscarmellose sodium, sodium starch glycolate, crospovidone	Supports rapid breakup and dissolution
Lubricant	Magnesium stearate, stearic acid, sodium stearyl fumarate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Film former	Hypromellose, hydroxypropyl cellulose	Enables a smooth, dye-free coating
Plasticizer	Polyethylene glycol, propylene glycol	Improves coating flexibility
Opacifier	Titanium dioxide, where used	Produces a white or opaque appearance
Capsule shell	Gelatin or hypromellose	Relevant to vegetarian, religious, and allergen claims

A dye-free tablet can use a conventional core formulation while replacing colored coating systems with an uncolored hypromellose film. An uncoated white tablet can reduce manufacturing complexity but may create greater exposure to odor, friability, ibuprofen taste, and tablet-marking requirements.

How should the excipient strategy address ibuprofen’s formulation properties?

Ibuprofen creates several formulation challenges despite its mature regulatory profile. It is poorly water soluble at low pH, hydrophobic, and present at a relatively high dose for a small immediate-release tablet. It can also create powder-flow, sticking, and dissolution variability during compression.

Direct compression strategy

Direct compression is commercially attractive because it reduces processing steps, equipment requirements, and manufacturing time. A typical platform can combine:

1. Microcrystalline cellulose or dibasic calcium phosphate for compactability.
2. Crospovidone or croscarmellose sodium for rapid disintegration.
3. Colloidal silicon dioxide for flow.
4. Magnesium stearate or sodium stearyl fumarate for lubrication.
5. A small amount of binder where tablet strength requires it.

The main risks are segregation, punch sticking, lubricant overmixing, and dissolution failure caused by excessive hydrophobicity.

Wet-granulation strategy

Wet granulation can improve content uniformity, flow, and tablet strength. It is more expensive and introduces additional controls for drying, residual moisture, granule size, and ibuprofen distribution. It may be appropriate where direct compression produces unacceptable hardness, friability, or dissolution results.

Solubility and dissolution strategy

For a conventional 200 mg immediate-release product, the target is reliable dissolution rather than a novel delivery system. Commercially relevant approaches include:

• Particle-size control
• Improved wetting
• Surfactant-assisted granulation
• Solid dispersion technology
• Salt or co-crystal approaches
• Amorphous or micronized ibuprofen
• Effervescent or liquid-filled formats

These approaches can support faster onset claims only when supported by comparative dissolution and clinical evidence. A faster dissolution profile does not automatically establish faster clinical pain relief.

What formulations are protected by patents?

The core ibuprofen molecule is off-patent, and conventional 200 mg tablets generally have limited patent exposure. The principal potential patent categories are formulation-specific rather than API-specific.

Relevant formulation patent categories

• Micronized or nanoparticulate ibuprofen
• Rapid-release or fast-onset formulations
• Ibuprofen lysine or other salt forms
• Soft-gel or liquid-filled capsules
• Taste-masked chewable tablets
• Pediatric liquid formulations
• Effervescent ibuprofen products
• Fixed-dose combinations
• Modified-release products
• Manufacturing processes that control particle size or granulation
• Packaging systems that improve moisture or oxygen stability

A formulation patent has commercial value only if its claims cover the marketed composition or process and remain enforceable in the relevant jurisdiction. A patent directed to a specific salt, particle-size distribution, dissolution threshold, or excipient ratio may not cover a standard dye-free tablet.

What is the patent and exclusivity position for dye-free ibuprofen 200 mg?

Protection category	Position for conventional dye-free ibuprofen 200 mg
API patent	Expired
Standard immediate-release tablet patent	Usually limited or absent for mature products
FDA new-drug exclusivity	Generally not applicable to monograph-compliant products
Orphan exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Formulation patent	Possible for specialized delivery systems
Process patent	Possible but dependent on manufacturing claims
Trademark protection	Possible for brand names and packaging
Trade-secret protection	Possible for process parameters and supplier specifications

There is no meaningful biosimilar pathway because ibuprofen is a chemically synthesized small molecule, not a biologic. Generic entry risk is therefore high for any standard immediate-release formulation.

When does dye-free ibuprofen lose exclusivity?

A conventional dye-free ibuprofen product does not normally have a meaningful remaining exclusivity period at the active-ingredient level. Market access is primarily controlled by FDA compliance, manufacturing capability, retailer qualification, private-label contracting, and brand recognition.

If the product is marketed under the OTC monograph pathway, the relevant commercial question is not the expiration of a product patent. It is whether the formulation, labeling, manufacturing controls, and facility compliance satisfy the applicable FDA requirements.[1]

A product marketed under an approved NDA can have product-specific Orange Book listings and exclusivity. That analysis is product-specific and cannot be applied automatically to every 200 mg ibuprofen product.

What is the Orange Book status of dye-free ibuprofen 200 mg?

The Orange Book status depends on the regulatory pathway and manufacturer. Standard OTC monograph products are not analyzed in the same way as prescription products with listed patents and Paragraph IV certifications.

Regulatory route	Orange Book and challenge implications
OTC monograph product	Usually no NDA patent-certification process comparable to an ANDA
Approved OTC NDA	May have an Orange Book listing and product-specific patent information
ANDA referencing an NDA	May require Paragraph IV, III, II, or I certification depending on listed patents
505(b)(2) application	May involve listed patents and exclusivity for the reference product
Private-label monograph product	Usually relies on monograph compliance and contract manufacturing

A company should not assume that the absence of an Orange Book listing proves the absence of all patent risk. It means the regulatory pathway differs from the standard prescription-generic model. Formulation, process, trademark, packaging, and unfair-competition issues may remain relevant.

Which companies are challenging dye-free ibuprofen 200 mg?

The market is typically challenged by generic and private-label manufacturers rather than by Paragraph IV litigants. Major competitive groups include:

• Large OTC brands
• Retailer-owned store brands
• Contract manufacturers
• Generic pharmaceutical companies
• E-commerce private labels
• Specialty manufacturers of softgels and liquid-filled capsules

The relevant competitors may sell products labeled as "dye-free," "coated," "easy to swallow," "vegan," "gluten-free," or "rapid release." Competitive differentiation often occurs at the SKU and retailer level rather than through legally distinct active ingredients.

What commercial opportunities exist for dye-free ibuprofen 200 mg?

Retail private label

Retailers can use dye-free ibuprofen as a low-complexity store-brand SKU. The product fits drugstore, grocery, club, mass-market, and e-commerce channels. The key procurement requirements are:

• Reliable FDA-compliant manufacturing
• Competitive landed cost
• Low complaint rates
• Stable supply of ibuprofen API
• Retail-ready packaging
• Bar-code and serialization compliance where applicable
• Consistent tablet appearance

Private-label buyers may prefer a platform that can support multiple package counts, including 24-, 40-, 50-, 100-, 200-, and 500-count configurations.

Clean-label and sensitive-consumer positioning

Dye-free positioning can appeal to consumers who avoid artificial colorants or seek simpler inactive-ingredient profiles. The strongest commercial proposition is a transparent label combined with a specific exclusion claim, such as:

• No artificial colors
• No FD&C dyes
• Gluten-free, if substantiated
• Lactose-free, if substantiated
• Vegetarian, if the dosage form permits
• Gelatin-free, for hypromellose capsules or tablets

Each claim requires control of raw-material specifications, supplier changes, cross-contamination risk, and label substantiation.

Pediatric and family formulations

A 200 mg tablet is generally intended for consumers age 12 and older. Family-oriented opportunities may include dye-free chewables, suspensions, or lower-strength tablets. These formats carry greater formulation risk because taste, viscosity, preservative systems, dose uniformity, and accidental-ingestion controls become more important.

A dye-free pediatric product must manage a commercial tradeoff: removing colorants may improve ingredient transparency but can reduce flavor recognition and consumer acceptance. Flavor systems, sweeteners, and taste masking become central excipient decisions.

Softgels and liquid-filled capsules

Liquid-filled ibuprofen softgels can provide a premium alternative to compressed tablets. Potential advantages include swallowability, differentiated appearance, and opportunities for rapid-dissolution positioning. Constraints include:

• Gelatin or alternative capsule-shell selection
• Fill compatibility
• Seal integrity
• Oxidative stability
• Plasticizer migration
• Higher manufacturing cost
• More complex packaging

A dye-free softgel still requires review of the capsule shell, printing ink, fill color, and packaging components.

How strong is the patent estate for dye-free ibuprofen 200 mg?

The patent estate is weak for a standard uncoated or conventionally film-coated immediate-release tablet. It can be stronger for a differentiated platform with measurable technical limitations.

Product type	Relative patent strength	Main defensibility
Standard dye-free tablet	Low	Cost, quality, supply, brand
Dye-free film-coated tablet	Low to moderate	Coating composition or process, if novel
Micronized rapid-release tablet	Moderate	Particle size, dissolution, process claims
Dye-free chewable	Moderate	Taste masking, texture, excipient system
Liquid-filled softgel	Moderate	Fill composition, shell, manufacturing process
Extended-release product	Higher	Release-control system and formulation claims
Combination analgesic	Moderate to high	Combination, dosing, and method-of-use claims

Patent value rises when the formulation solves a measurable problem that a competitor cannot easily design around. A generic claim such as "a dye-free ibuprofen tablet" is unlikely to provide durable protection without technical limitations and patentable novelty.

What manufacturing and IP barriers affect market entry?

The main barriers are operational rather than molecule-level IP barriers.

Manufacturing barriers

• Ibuprofen sticking to tablet tooling
• Variable powder flow
• Inadequate blend uniformity
• Slow or inconsistent dissolution
• Tablet capping and friability
• Coating defects
• Odor migration
• Moisture sensitivity
• Supplier inconsistency
• Packaging failures

The formulation should be tested across commercial-scale compression speeds, tooling configurations, humidity conditions, and API particle-size lots. A laboratory formulation that performs well at low-speed compression may fail at production scale.

Intellectual-property barriers

• Active formulation patents for rapid-release systems
• Process patents covering micronization or granulation
• Trademark rights for product names
• Trade dress and package-design rights
• Licensing rights for proprietary excipient technologies
• Patent rights in non-U.S. markets
• Combination-product patents

Freedom-to-operate analysis should cover the exact API form, particle-size distribution, excipient ratios, process conditions, capsule or coating system, and proposed claims.

How does dye-free ibuprofen compare with other OTC analgesics?

Product	Typical strength	Dye-free opportunity	Key formulation issue
Ibuprofen	200 mg	Strong	Poor water solubility and high dose load
Acetaminophen	325 or 500 mg	Strong	High dose load and hepatotoxicity labeling
Naproxen sodium	220 mg	Moderate	Salt form, dissolution, longer dosing interval
Aspirin	81 or 325 mg	Moderate	Moisture sensitivity and gastric tolerability
Combination analgesics	Variable	Strong but complex	Labeling, interaction, and claim restrictions

Ibuprofen has an attractive commercial balance: broad consumer recognition, low unit cost, multiple dosage forms, and no biosimilar or active-ingredient exclusivity barrier. Its main disadvantages are formulation complexity and NSAID-related safety labeling.

What is the generic launch risk for dye-free ibuprofen 200 mg?

Generic launch risk is high for conventional tablets because competitors can usually develop an alternative formulation without infringing a meaningful API patent. The risk profile changes for specialized products.

Standard tablet

Expected competitive dynamics include rapid price comparison, retailer bidding, and limited brand loyalty. Manufacturing reliability and packaging cost are more important than patent exclusivity.

Premium tablet or softgel

A differentiated product may sustain better pricing if it demonstrates easier swallowing, cleaner inactive-ingredient positioning, or faster dissolution. The claims must remain consistent with FDA labeling requirements and supporting evidence.

Pediatric product

The opportunity is commercially attractive but technically more demanding. Taste masking, dosing accuracy, and safety packaging can create stronger consumer and retailer differentiation than the "dye-free" claim alone.

How should companies prioritize excipient development?

A practical development sequence is:

1. Select the dosage form and target consumer.
2. Define the prohibited and permitted excipient list.
3. Screen API particle size and flow properties.
4. Establish a dissolution and disintegration target.
5. Evaluate direct compression before wet granulation.
6. Screen lubricants for sticking and dissolution impact.
7. Confirm inactive ingredients against FDA’s Inactive Ingredient Database and applicable compendial requirements.[3]
8. Conduct accelerated and long-term stability studies.
9. Validate dye-free and allergen-related claims through supplier controls.
10. Build a formulation that can scale across multiple package counts.

Excipient selection should be based on function, supply continuity, regulatory acceptability, and claim compatibility. Replacing a dye with an opaque coating or unqualified colorant does not create a meaningful clean-label product.

What regulatory status applies to dye-free ibuprofen 200 mg?

The product must comply with the applicable FDA OTC monograph, current good manufacturing practice requirements, labeling rules, adverse-event obligations, and drug listing requirements.[1,4] The Drug Facts label must state the active ingredient, purpose, uses, warnings, directions, inactive ingredients, and other required information.

The product cannot rely on a "natural," "clean," or "sensitive" positioning to avoid drug requirements. It remains an FDA-regulated drug product because ibuprofen is an active analgesic ingredient.

What licensing opportunities exist?

Licensing opportunities are more likely to involve formulation technology and distribution than the ibuprofen molecule. Potential targets include:

• Rapid-dissolution excipient platforms
• Taste-masking technology
• Hypromellose capsule systems
• Dye-free coating systems
• Micronized API supply
• Pediatric suspension technology
• Contract manufacturing and packaging
• Retailer-exclusive product development

A licensing deal is most defensible when the technology produces a validated benefit, such as improved dissolution, reduced tablet sticking, longer stability, or a differentiated dosage form. A simple dye-free tablet usually supports a supply or private-label manufacturing agreement rather than a high-value patent license.

Key Takeaways

• Dye-free ibuprofen 200 mg is primarily a formulation and commercial execution opportunity.
• The API is mature and does not provide meaningful current exclusivity for conventional products.
• Standard immediate-release tablets have low patent strength and high generic-entry risk.
• The most useful excipient platform combines robust compression, rapid disintegration, acceptable dissolution, and transparent ingredient control.
• Direct compression is the preferred initial manufacturing route when flow and sticking can be controlled.
• Commercial upside is strongest in retailer private label, clean-label positioning, pediatric formats, and premium softgels.
• Dye-free claims do not automatically establish gluten-free, gelatin-free, lactose-free, or artificial-flavor-free status.
• Orange Book and Paragraph IV analysis depends on whether the product is marketed under an OTC monograph, NDA, ANDA, or 505(b)(2) pathway.
• Formulation, process, packaging, trademark, and manufacturing know-how are more relevant than API patent protection.
• No biosimilar risk exists because ibuprofen is a small-molecule drug.

FAQs

Is dye-free ibuprofen 200 mg the same as regular ibuprofen?

Yes. The therapeutic active ingredient is the same, but the inactive-ingredient system excludes color additives used in some conventional products.

Can a dye-free ibuprofen tablet be patented?

A generic dye-free claim is unlikely to provide strong patent protection by itself. Patentability is more plausible when the product includes a novel formulation, particle-size distribution, dissolution profile, manufacturing process, or delivery system.

Does dye-free ibuprofen contain titanium dioxide?

It may. Titanium dioxide is an opacifier rather than a conventional dye, and its presence depends on the specific product label. The complete inactive-ingredient list must be reviewed.

Is dye-free ibuprofen suitable for children?

A 200 mg tablet is generally labeled for consumers age 12 and older. Younger children require age-appropriate dosage forms and dosing based on the product label or a healthcare professional’s direction.

What is the most defensible commercial advantage for dye-free ibuprofen?

The strongest advantages are transparent inactive ingredients, reliable quality, retailer-specific packaging, compliant clean-label claims, and a dosage form that improves swallowing or dissolution without materially increasing cost.

References

1. U.S. Food and Drug Administration. (2024). OTC monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.fda.gov
2. DailyMed. (2024). Ibuprofen 200 mg tablet labeling. National Library of Medicine. https://dailymed.nlm.nih.gov
3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
4. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-343